Capital Raising

mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).

Leadership read: mbiomics's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across EMEA.

curated · 2026-10-16 · context →

Alchemab Therapeutics received €29.3M from the British Business Bank to advance its clinical pipeline (as reported in a roundup of European biotech financings).

Leadership read: Fresh capital is a hiring signal before it is anything else. For Alchemab Therapeutics, a raise in the sector funds leadership depth, scale, go-to-market and operational rigour, rather than any single appointment. Watch where Alchemab Therapeutics hires first across EMEA; that is where the capital is really pointed.

curated · 2026-10-16 · context →

Nauta secured a €60M first close for its sixth fund to back European software and deeptech startups.

Leadership read: Nauta's raise resets the leadership agenda more than the balance sheet. Capital into the sector buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across EMEA.

curated · 2026-10-16 · context →

Nvidia plans a minority investment in UK startup Boltz.

Leadership read: Fresh capital is a hiring signal before it is anything else. For Boltz, a raise in the sector funds leadership depth, scale, go-to-market and operational rigour, rather than any single appointment. Watch where Boltz hires first across EMEA; that is where the capital is really pointed.

curated · 2026-10-16 · context →

Nvidia plans a minority investment in UK quantum-software company Riverlane.

Leadership read: Fresh capital is a hiring signal before it is anything else. For Riverlane, a raise in the sector funds leadership depth, scale, go-to-market and operational rigour, rather than any single appointment. Watch where Riverlane hires first across EMEA; that is where the capital is really pointed.

curated · 2026-10-16 · context →

Nasdaq-listed Scinai Immunotherapeutics closed a $4.0 million financing via private placement and warrant inducement, funding its CDMO operations and immunology therapeutic development.

Leadership read: Scinai Immunotherapeutics Ltd.'s raise resets the leadership agenda more than the balance sheet. Capital into the sector buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across EMEA.

curated · 2026-10-16 · context →

Oslo-based open finance company Neonomics secured $4 million from existing shareholders to fund its next growth phase after a restructuring that cut its operating cost base by nearly 50%.

Leadership read: Neonomics's raise resets the leadership agenda more than the balance sheet. Capital into the sector buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across EMEA.

curated · 2026-10-16 · context →

Jewish National Fund-USA reported raising $192 million in fiscal 2026 (year ended Sept 30, 2026), taking its three-year total past $700 million, with a donor base of 664,033 and a goal of engaging one million supporters over the next decade.

Leadership read: Fresh capital is a hiring signal before it is anything else. For Jewish National Fund-USA, a raise in the sector funds leadership depth, scale, go-to-market and operational rigour, rather than any single appointment. Watch where Jewish National Fund-USA hires first across EMEA; that is where the capital is really pointed.

curated · 2026-10-16 · context →

Oslo-based AI-native engineering services firm Solvera raised a $6.3M pre-seed round led by Seedcamp, with participation from Inception Fund, Momentum, PSV, Sondo, OBOS Ventures, Construct Venture and The Nordic Web Ventures, plus angels including Spacemaker founders.

Leadership read: Fresh capital is a hiring signal before it is anything else. For Solvera, a raise in the sector funds leadership depth, scale, go-to-market and operational rigour, rather than any single appointment. Watch where Solvera hires first across EMEA; that is where the capital is really pointed.

curated · 2026-10-16 · context →

Salience Labs secured $125M to scale photonic chips for AI data centres.

Leadership read: Salience Labs's raise resets the leadership agenda more than the balance sheet. Capital into the sector buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across EMEA.

curated · 2026-10-16 · context →

EZO raised €150M in debt financing.

Leadership read: Fresh capital is a hiring signal before it is anything else. For EZO, a raise in the sector funds leadership depth, scale, go-to-market and operational rigour, rather than any single appointment. Watch where EZO hires first across EMEA; that is where the capital is really pointed.

curated · 2026-10-16 · context →

Strive priced an upsized $630M IPO of SATS preferred stock.

Leadership read: Strive's raise resets the leadership agenda more than the balance sheet. Capital into the sector buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.

curated · 2026-10-16 · context →